Currently, XEN-D0501, a TRPV1 antagonist, is undergoing clinical trials to assess its efficacy in regulating blood glucose and mitigating T2D-related inflammatory complications (98). The gene discussed is TRPV1; the disease is type 2 diabetes mellitus.